Methods
We carried out a retrospective analysis of hospital records of children who received Peg-GCSF for PBSC mobilization between May 2016 to September 2020 in our unit. All children received single subcutaneous dose of Peg-GCSF 100 microgram/kg 24-48 hours after completion of mobilisation chemotherapy and proceeded to PBSC harvest once CD34 count was >10/microliter in the peripheral blood. All PBSC collection were performed on COMTEC (Fresenius Kabi, Germany) apheresis machine. The product sample was taken at the end of PBSC collection from the apheresis collection bag for enumerating CD34 count in the final product. The stem cells were cryopreserved for autologous transplant. Patients were monitored for possible adverse effects of Peg-GCSF viz. bone pain, headache, skin rash, transient hypotension, splenic enlargement, capillary leak syndrome characterized by puffiness, difficulty in breathing, decreased urine output (1,6,13,15).